Spatial location of local recurrences after mastectomy: a systematic review

Kaidar‐Person, Orit; Poortmans, Philip; Offersen, Birgitte Vrou; Siesling, Sabine; Sklair‐Levy, Miri; Meattini, Icro; Ruysscher, Dirk De; Kühn, Thorsten; Boersma, Liesbeth

doi:10.1007/s10549-020-05774-4

Cited by 31 publications

(30 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current challenges include the integration and optimisation of radiotherapy with breast reconstruction, identifying patients in whom radiotherapy can be omitted without jeopardising outcomes including quality of life, and selective treatment escalation in patients at high risk, especially in case of resistance to neoadjuvant therapy. 31,[103][104][105] The ultimate aim is to achieve individualised, risk-adapted radiotherapy, combining a variety of biomarkers with novel applications of artificial intelligence. [106][107][108] Early breast cancer: systemic therapy…”

Section: Early Breast Cancer: Locoregional Therapymentioning

confidence: 99%

Breast cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Breast cancer is still the most common cancer worldwide. But the way breast cancer is viewed has changed drastically since its molecular hallmarks were extensively characterised, now including immunohistochemical markers (eg, ER, PR, HER2 [ERBB2], and proliferation marker protein Ki-67 [MKI67]), genomic markers (eg, BRCA1, BRCA2, and PIK3CA), and immunomarkers (eg, tumour-infiltrating lymphocytes and PD-L1). New biomarker combinations are the basis for increasingly complex diagnostic algorithms. Neoadjuvant combination therapy, often including targeted agents, is a standard of care (especially in HER2-positive and triple-negative breast cancer), and the basis for de-escalation of surgery in the breast and axilla and for risk-adapted post-neoadjuvant strategies. Radiotherapy remains an important cornerstone of breast cancer therapy, but de-escalation schemes have become the standard of care. ER-positive tumours are treated with 5-10 years of endocrine therapy and chemotherapy, based on an individual risk assessment. For metastatic breast cancer, standard therapy options include targeted approaches such as CDK4 and CDK6 inhibitors, PI3K inhibitors, PARP inhibitors, and anti-PD-L1 immunotherapy, depending on tumour type and molecular profile. This range of treatment options reflects the complexity of breast cancer therapy today.

show abstract

Section: Early Breast Cancer: Locoregional Therapymentioning

confidence: 99%

Breast cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Importantly, most of the local recurrences are subcutaneously in the chest wall, followed by the skin itself, and mostly at the area around the mastectomy scar (e.g., Fig. 2) [7]. The latter could be a result of tumour cell seeding at time of the mastectomy procedure, or a recurrence in the subcutaneous lymphatic plexus infiltrating the skin [23e26].…”

Section: Radical and Modified Radical Mastectomymentioning

confidence: 99%

“…New radiation treatment planning and imaging systems allow dose distributions based on the anatomically defined estimated risk of residual cancer cells, and surgical techniques. Therein lays a need for better understanding of the surgical techniques to define the target volumes for PMRT [7].…”

Section: Introductionmentioning

confidence: 99%

A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges

et al. 2021

Self Cite

View full text Add to dashboard Cite

The current review paper was written in collaboration with breast cancer surgeons from the European Breast Cancer Research Association of Surgical Trialists (EUBREAST), a breast pathologist from the Danish Breast Cancer Group (DBCG), and representatives from the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer course. Herein we summarize the different mastectomies and reconstruction procedures and define high-risk anatomical areas for breast cancer recurrences, to further specify the challenges in the surgical procedure, histopathological evaluation, and target volumes in case of postmastectomy irradiation, as recommended by the ESTRO guidelines according to the surgical procedure. The paper has original figures and illustrations for all disciplines for in-depth understanding of the differences between the procedures.

show abstract

“…This native-skin subcutaneous tissue contains the subcutaneous lymphatic plexus, which is the main location for recurrences after mastectomy. 8 The oncological safety from randomized trials of these procedures in high-risk BC patients is lacking, with new reports suggesting a high local recurrence rate in the setting of immediate reconstruction. [9][10][11][12] 10 Therefore, at Meirav Breast center, and public health policy coverage, our high-risk surveillance protocol includes a physical breast examination by a breast surgeon every 6 months and alternating imaging of breast ultrasounds and breast MRI every 6 months.…”

Section: The American College Of Radiology (Acr) Appropriatenessmentioning

confidence: 99%

Post‐mastectomy surveillance of BRCA1 / BRCA 2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients

et al. 2021

View full text Add to dashboard Cite

Female BRCA1/BRCA2 mutation carriers may elect bilateral risk-reducing mastectomy.There is a paucity of data on yield of imaging surveillance after risk-reducing mastectomy. This retrospective study focused on female BRCA1/BRCA2 mutation carriers who underwent bilateral mastectomy either as primary preventative, or as secondary preventative, after breast cancer diagnosis. All participants underwent breast imaging at 6-to 12-month intervals after mastectomy. Data on subsequent breast cancer diagnosis and timing were collected and compared between the groups. Overall, 184 female mutation carriers (134 BRCA1, 45 BRCA2, 5 both BRCA genes) underwent bilateral mastectomy after initial breast cancer diagnosis, between April 1, 2009 and How to cite this article: Kanana N, Ben David MA, Nissan N, et al. Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.

show abstract

Spatial location of local recurrences after mastectomy: a systematic review

Abstract: Purpose We performed a systematic review to document the spatial location of local recurrences (LR) after mastectomy.

Cited by 31 publications

References 60 publications

Breast cancer

Breast cancer

A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges

Post‐mastectomy surveillance of BRCA1 / BRCA 2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients

Contact Info

Product

Resources

About